SCHEMBL2920795

SCHEMBL2920795

Cc1cccc2cnc(Nc3cccc(C(=O)O)c3)nc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHOA P61586 1/20 0.57
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
ABL1 P00519 1/20 0.53
BCR P11274 1/20 0.53
PRKCA P17252 1/20 0.53
AURKA O14965 6/20 0.51
EGFR P00533 2/20 0.51
BTK Q06187 1/20 0.51
FGFR1 P11362 1/20 0.51
IKBKB O14920 1/20 0.48
CSNK2A2 P19784 1/20 0.48
CSNK2B P67870 1/20 0.48
CSNK2A1 P68400 1/20 0.48
RAD52 P43351 1/20 0.47
MAP3K5 Q99683 1/20 0.47
TP53 P04637 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SYK P43405 1/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2919019 0.89 SYK (0.53) BTKSYK
SCHEMBL2913046 0.88 ABL1 (0.56) NPC1RAB9AABL1BCREGFR
SCHEMBL27946499 0.87 AURKA (0.56) NPC1RAB9AAURKACSNK2A2CSNK2B
SCHEMBL27929053 0.85 RHOA (0.54) RHOANPC1RAB9AABL1BCR
SCHEMBL27929015 0.85 SMN1; SMN2 (0.64) NPC1RAB9AFGFR1TP53SYK
SCHEMBL28809973 0.84 RHOA (0.53) RHOANPC1RAB9AABL1BCR
SCHEMBL27929004 0.84 MAPK3 (0.52) NPC1RAB9AAURKACSNK2A2CSNK2B
SCHEMBL27946487 0.84 LRRK2 (0.43) NPC1RAB9AAURKACSNK2A2CSNK2B
SCHEMBL2919202 0.82 MAP3K5 (0.70) ABL1AURKAEGFRBTKCSNK2A1
SCHEMBL27946421 0.82 SRC (0.59)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103435594-A 2-amino-quinazolines PLK1 (Polo-like kinase1) inhibitor and application thereof UNIV CHINA PHARMA 2013-12-11 CN disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K RHOA 2451/4885NPC1 3804/4885RAB9A 1494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.